1 Role of monocytes in endothelial glycocalyx shedding during Puumala orthohantavirus

- 2 infection
- 3
- Luz E. Cabrera^{1*}, Isaac Polanco², Johanna Tietäväinen^{3,4}, Satu Mäkelä^{3,4}, Olli Vapalahti^{1,5}, 4
- Antti Vaheri¹, Jukka Mustonen^{3,4} and Tomas Strandin^{1,5} 5
- 6
- 7 ¹Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
- 8 ²Universidad Iberoamericana (UNIBE), Santo Domingo, Dominican Republic.
- 9 ³Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.
- 10 ⁴Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
- 11 ⁵Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
- 12
- 13 *Corresponding author.
- 14

15 Abstract

16 Vascular leakage characterizes Puumala orthohantavirus (PUUV)-caused hemorrhagic fever with renal syndrome (HFRS). Disruption in the endothelial glycocalyx layer, which protects 17 blood vessels from increased vascular leakage into tissues, may contribute to disease severity 18 19 during acute PUUV-HFRS. Recent evidence suggests that increased heparanase (HPSE) activity could play a role in glycocalyx degradation. Additionally, dynamic changes in 20 21 monocyte populations, especially a decrease in endothelium "patrolling" CD14⁺CD16⁺ 22 nonclassical monocytes (NCMs) are observed in acute PUUV-HFRS. To investigate HPSE 23 expression levels in different monocyte subsets and their relationship to the numbers of 24 circulating endothelial cells (CECs) as marker of glycocalyx degradation during PUUV-HFRS, 25 we analyzed patient peripheral blood mononuclear cells collected at acute and recovery stages 26 of the disease by flow cytometry. CECs were significantly increased in acute PUUV-HFRS NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 patients, and gradually decreased towards the postacute and recovery phases. Moreover, we 28 identified significant correlations between CECs, the frequencies of different monocyte subsets and their HPSE expression, and clinical parameters. The decrease in HPSE expressing NCMs 29 30 correlated with plasma HPSE levels, indicating a potential role for monocytes in modulating 31 endothelial glycocalyx shedding. Furthermore, co-culture experiments suggested PUUVinfected endothelial cells (ECs) as regulators of monocyte HPSE expression. The study 32 33 enhances understanding of EC and monocyte dynamics during PUUV-HFRS, providing insights into immune responses and potential vascular complications. Subtle variations in 34 35 monocyte subsets emphasize their possible variable roles in disease progression and changes 36 throughout the disease course. Overall, the study contributes to unraveling the complex interactions between viral infections, immune responses, and vascular dynamics, guiding 37 38 future investigations and interventions in PUUV-HFRS-associated vascular complications and 39 glycocalyx shedding in the kidneys.

40 Introduction

41

The dynamic interplay between viral infections and the vascular system has been a subject of 42 43 increasing interest, particularly in the context of viral diseases with diverse clinical manifestations (Fosse et al., 2021). Among these we find Puumala virus (PUUV), which causes 44 a relatively mild form of hemorrhagic fever with renal syndrome (HFRS) (Vaheri et al., 2023). 45 46 Despite the non-cytopathic effect of PUUV infection in endothelial cells (EC) and monocytes (Temonen et al., 1993), which play a key role in vascular integrity, the infection leads to 47 48 remarkable vascular complications evidenced by capillary permeability, increased coagulation 49 and fibrinolysis, thrombocytopenia and shedding of the endothelial glycocalyx (EGC) 50 components (Hepojoki et al., 2014).

51

The EGC disruption is proposed as a potential factor driving capillary leakage in acute HFRS 52 53 (Connolly-Andersen et al., 2014; Tietäväinen et al., 2021; Du et al., 2023). The EGC acts as a 54 crucial interface between circulating blood components and the endothelium (Reitsma et al., 2007), maintaining the vascular integrity and influencing its permeability. The enzyme 55 56 heparanase (HPSE) cleaves heparan sulfate molecules and acts as a major mediator in the degradation of the EGC (Becker et al., 2015; Masola et al., 2022). The role of HPSE in 57 compromising vascular integrity in viral diseases has been recognized, including PUUV-HFRS 58 59 (Kinaneh et al., 2021; Cabrera et al., 2022; Drost et al., 2022). Further, EGC damage has been proposed as a mechanism linking hyperglycemia with disease severity in HFRS (Tietäväinen 60 et al., 2021). During other viral diseases such as COVID-19, altered vascular permeability may 61 62 be responsible in the detachment of ECs associated with disease severity (Guervilly et al., 2020; Varga et al., 2020; Kinaneh et al., 2021; Drost et al., 2022). This detachment not only facilitates 63 the dissemination of the virus but also impairs vascular reactivity and nitric oxide (NO) 64

production, crucial for blood vessel relaxation and vascular homeostasis by preventingcoagulation and inflammation.

67

Monocytes, as key players in the immune response, exhibit remarkable heterogeneity, with 68 distinct subsets playing different roles in immune response modulation, tissue homeostasis, and 69 70 pathogen defense (Williams et al., 2023). Notably, distinct monocyte subsets assume varying 71 roles in both steady-state and pathological conditions. Classical monocytes (CM, expressing CD14⁺⁺CD16⁻) primarily initiate innate immune responses, engaging in phagocytosis and 72 73 migration through the expression of chemokines, scavenger receptors, and proinflammatory 74 cytokines (Gren et al., 2015). Intermediate monocytes (IM, CD14⁺⁺CD16⁺), on the other hand, are linked to antigen processing, presentation, monocyte activation, inflammation, and 75 76 differentiation (Zawada et al., 2011), and nonclassical monocytes (NCM, CD14⁺CD16⁺), are 77 unique in their patrolling behavior, particularly in surveilling vasculature and thus interacting with the endothelium (Cros et al., 2010). Importantly, monocyte translocation through vascular 78 79 bed requires EGC degradation mediated by HPSE, which is expressed on monocyte cell surface 80 (Sasaki et al., 2004) and suggests that monocytes are major source of HPSE activity.

81

In the context of acute PUUV-HFRS, our previous research revealed dynamic changes in monocyte populations. NCMs are significantly diminished in the circulation during acute PUUV-HFRS by rapidly redistributing to affected tissues during infection, accompanied by an increase in CMs and IMs in blood (Vangeti et al., 2021). This NCM redistribution leads to inflammation and tissue damage, particularly in the kidneys during acute PUUV-HFRS, suggesting their involvement in renal pathology.

89 In the present study, we hypothesized that monocyte populations may play a crucial role in the 90 increased expression of HPSE, thereby contributing to the breakdown of the endothelial glycocalyx and exacerbating vascular complications in PUUV-HFRS (Sironen et al., 2017). By 91 92 investigating the intricate mechanisms involving monocyte subsets and HPSE expression, our 93 research aims to shed light on the complex interplay between immune responses and vascular 94 complications during PUUV infection. These findings not only contribute to a deeper 95 understanding of the pathophysiology of this disease, but also lay the foundation for potential therapeutic interventions in the future, to alleviate the vascular complications associated with 96 97 this viral illness.

99 Materials & Methods

100

Ethics statement. The Ethics Committees of Tampere University Hospital (permit number
R04180) and Hospital District of Helsinki and Uusimaa 100 (HUS/853/2020, HUS/1238/2020)
approved the use of patient samples. All subjects gave written informed consent in accordance
with the Declaration of Helsinki.

105

Patient population. The study material consisted of plasma, urine, and PBMCs from 106 107 hospitalized, serologically confirmed acute PUUV infection at Tampere University Hospital, 108 Finland, between 2005 and 2009. Patient samples were collected from a cohort of 25 individuals at different time points, which included the acute phase of the disease for samples 109 110 taken during hospitalization, the postacute/convalescent phase for samples taken 15 days after 111 discharge, and the full recovery phase for samples taken 6 months and one year after the acute phase. Full recovery phase samples were used as controls. Standard methods were employed 112 113 to determine daily white blood cell (WBC) count, plasma C-reactive protein (CRP), and serum creatinine concentrations at the Laboratory Centre of the Pirkanmaa Hospital District 114 (Tampere, Finland). Details about the clinical and laboratory data of the patient cohort can be 115 found in Table 1. 116

- 117 Table 1. Clinical and laboratory data during hospitalization in patients with acute PUUV
- 118 *infection.* BP = blood pressure; WBC = white blood cells; max = maximum; min = minimum.
- 119

| Parameter (unit) | Range (Median <u>+</u> SD) | Reference values |
|-----------------------------|-------------------------------|-------------------------|
| | PBMCs (n = 25) | |
| Age (years) | 25 – 67 (40 <u>+</u> 13) | - |
| Gender (Male:Female) | 15:10 | _ |
| After onset of fever (days) | 3 – 7 (5 <u>+</u> 1) | - |

| Duration of fever (days) | 3 – 9 (7 <u>+</u> 2) | - |
|---|------------------------------|----------------------------------|
| Length of hospital stay (days) | 2 – 25 (4 <u>+</u> 4.5) | |
| Max Systolic BP (mmHg) | 102 – 208 (136 <u>+</u> 26) | < 120 |
| Max Diastolic BP (mmHg) | 57 – 103 (84 <u>+</u> 112) | < 80 |
| Min Systolic BP (mmHg) | 74 – 139 (110 <u>+</u> 14) | < 120 |
| Min Diastolic BP (mmHg) | 40 – 93 (67 <u>+</u> 12) | - |
| Max plasma creatinine (µmol/L) | 51 – 1499 (137 <u>+</u> 302) | Male: 62 – 115 / Female: 53 – 97 |
| Max Hematocrit (%) | 36 – 52 (44 <u>+</u> 5) | Male: 39 – 50 / Female: 35 – 46 |
| Min Hematocrit (%) | 25 – 44 (36 <u>+</u> 5) | Male: 39 – 50 / Female: 35 – 46 |
| Max WBC (E9/L) | 7 – 26 (11 <u>+</u> 5) | 3 - 8 |
| Min Thrombocytes (E9/L) | 15 – 118 (61 <u>+</u> 29) | 150 - 360 |
| Weight change (kg) | $0 - 10 (1 \pm 3)$ | - |
| Max C-reactive protein (mg/L) | 16 – 267 (89 <u>+</u> 60) | < 4 |
| Urinary albumin:creatinine ratio (mg/g) | $0-61(1 \pm 12)$ | < 30 |

120

Flow cytometry. Frozen PUUV patient PBMCs were thawed in a 37°C water bath for 5 min, then washed with RPMI-1640 (Sigma Aldrich) supplemented with 10% inactivated FCS, 100 IU/ml of penicillin, 100 μ g/ml of streptomycin, 2mM of L-glutamine, and 100 μ g/ml DNAse I (Sigma Aldrich). After a 10 min incubation at RT, the cells were washed once with the conditioned medium and once with PBS-EDTA (PBS with 2 mM EDTA), followed by cell quantification using Bio-Rad cell counter TC20.

127 One to three million PBMCs were incubated in 1% FCS and FcR blocking reagent 128 (BioLegend), and the cells stained for 30 min at RT with a cocktail of fluorescent-dye 129 conjugated anti-human mouse mAbs recognizing cell surface antigens and a dead cell marker 130 (antibody panel detailed in Table 2). After staining, the cells were washed with PBS-EDTA 131 and fixed with 1% paraformaldehyde before FACS analysis with a 4-laser (405, 488, 561 and

132 637 nm) Quanteon Novocyte (Agilent Technologies). The FACS data was analyzed with 133 FlowJo 10.8. The datasets were normalized independently and concatenated. Cell populations 134 were identified by Uniform Manifold Approximation and Projection for Dimension Reduction 135 (UMAP), allowing for their unsupervised identification, based on the detection of different 136 fluorochromes used in the flow cytometry panel. To generate UMAP plots, the minimum 137 distance was set at 0.5 and the nearest neighbors' distance was set at 15, using a Euclidean 138 vector space. Clusters were then identified using the phenograph plugin.

- 139
- 140 *Table 2. Flow cytometry antibody panel.*
- 141

| Marker | Fluorochrome | Clone | Company |
|--------------|----------------------|-------------|-----------------------|
| CD123 | PE | 6H6 | BioLegend |
| CD19 | PE | LT19 | Immunotools |
| CD3 | PE | OKT3 | BD Biosciences |
| CD56 | PE | B159 | BD Biosciences |
| Heparanase 1 | FITC | HPA1 (E-10) | Santa Cruz Technology |
| Live/Dead | FVS 570 | - | BD Biosciences |
| CD14 | PE-Cy7 | M5E2 | BD Biosciences |
| CD34 | APC | 4H11 | Invitrogen |
| CD45 | V450 | 2D1 | Invitrogen |
| CD133 | Brilliant Violet 605 | TMP4 | Invitrogen |
| CD146 | Brilliant Violet 711 | P1H12 | BioLegend |
| CD16 | Brilliant Violet 786 | 3G8 | BD Biosciences |
| HLA DR | BB700 | G46-6 | BD Biosciences |
| CD138 | APC-CY7 | 44F9 | MACS Miltenyi |

143 *In vitro* coculture. Blood microvascular endothelial cells (BECs) were obtained from Lonza and maintained in endothelial basal medium (EBM-2) supplemented with SingleQuots[™] Kit 144 containing 5% fetal bovine serum (FBS), human endothelial growth factor, hydrocortisone, 145 vascular endothelial growth factor, human fibroblast growth factor-basic, ascorbic acid, R³-146 insulin like growth factor-1, gentamicin and amphotericin-B (Lonza). For experiments the cells 147 were used at passage 8. BECs were infected for 3 days with live or UV-inactivated PUUV 148 149 (strain Suo). Multiplicity of infection was 1 as calculated by using Vero E6 cells. Monocytes were isolated from PBMCs obtained from healthy volunteers using CD14 magnetic beads 150 151 (Miltenyi Biotec) according to the protocol provided by the manufacturer. Isolated monocytes 152 were co-cultured with infected BECs in a 3:1 ratio (with monocyte concentration of 1 million/ml) for 24-hr. Cell culture supernatant was collected after which cells were pelleted by 153 154 centrifugation 400g for 5 min and stained for flow cytometry as described above.

155

ELISA. Syndecan-1 was measured from urine of patients using an ELISA kit purchased from
R&D systems following the manufacturer's protocol (Human Syndecan-1 DuoSet, Catalog #:
DY2780; Bio-techne, Abingdon, UK).

159

HPSE Measurement Assay. HPSE levels from patient plasma and urine was measured through the enzyme's ability to cleave HS, which was quantified with the use of a standard curve. In detail, Nunc maxisorp flat-bottom 96-well plates (Thermo scientific; Breda, The Netherlands) were coated with 10 μ g/mL heparan sulfate from bovine kidney (HSBK) (Sigma– Aldrich; Zwijndrecht, The Netherlands) in coating buffer (3.3 M ammonium sulfate ((NH₄)₂SO₄)), for 1h at 37 °C. Subsequently, plates were washed with PBS supplemented with 0.05% Tween 20 (PBST) and blocked with 1% BSA in PBS at RT. After blocking, plates were

167 washed with PBST, followed by a final washing step with PBS. Plasma and urine samples were then incubated for 2 h at 37 °C, in a 1:4 dilution in HPSE buffer (50 mM citric acid-sodium 168 citrate, 50 mM NaCl, 1 mM CaCl2 at pH 5.0). Next, plates were washed with PBST and 169 170 incubated with primary mouse anti-rat IgM HS antibody JM403 (Amsbio; Abingdon, United Kingdom, cat. no. #370730-S, RRID: AB 10890960, 1 µg/mL in PBST) at RT for 1 h, washed 171 with PBST and then incubated with secondary goat anti-mouse IgM HRP antibody (Southern 172 173 Biotech; Uden, The Netherlands, cat. no. #1020–05, RRID: AB_2794201, 1:10,000 dilution in PBST) for 1h at RT and washed with PBST once again. Finally, 3,3',5,5'-tetramethylbenzidine 174 175 (TMB) substrate (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added to the plates, the 176 reaction was stopped by the addition of 0.5 M sulfuric acid, and absorbance was measured at 450 nm. The HPSE concentration in the plasma and urine of patient samples, as well as from 177 178 podocyte cultures, was compared to a standard curve of recombinant human HPSE (Bio-179 techne; Abingdon, UK, Cat#7570-GH-005). Urine concentrations measured were then 180 normalized by dividing the values by creatinine (heparanase:creatinine ratio).

181

Statistical analyses. Statistical analyses were performed using GraphPad Prism 8.3 software (GraphPad Software, San Diego, CA, USA). Statistically significant correlations between parameters were assessed by calculating Spearman's correlation coefficients, and differences between groups were assessed with Kruskall-Wallis or ordinary 2-way ANOVA analyses, depending on sample distribution and the number of groups analyzed.

187

189 **Results**

190 Circulating mature and progenitor endothelial cells are increased during acute PUUV-

- 191 **HFRS**
- 192

Quantitative analysis of peripheral blood mononuclear cells (PBMCs) using flow cytometry 193 194 (gating strategy shown in Fig. 1A) revealed dynamic alterations in endothelial cell (EC) counts 195 across different stages of PUUV-HFRS. During the acute phase of PUUV-HFRS (sampling at 196 1st day of hospitalization), a statistically significant increase in EC counts (both circulating 197 endothelial cells, CECs, and circulating endothelial progenitors, CEPs, Fig. 1B-C) was 198 observed compared to healthy recovery stage (12 months post-infection). The EC counts then 199 gradually decreased in the postacute phase but remained slightly elevated compared to disease resolution. Notably, in the recovery stages at 6 months and 12 months post-infection, EC counts 200 201 reached their lowest levels, with no significant difference between these two time points. These 202 data suggest compromised endothelial integrity in PUUV-HFRS.

203

The acute PUUV-HFRS patient samples were further stratified based on days after onset of fever (aof) at the time when samples were collected. This allowed us to observe kinetic differences between CEC and CEP responses (Fig. 1D-E). Surprisingly, the peak increase in CEPs occurred earlier as compared to CECs (5 vs. 7 days aof), which suggests either that vascular integrity is being compromised before detectable CEC response occurs in our assay or that CEPs mature directly into CECs during acute PUUV-HFRS.

210

211

213 Dynamic modulation of monocyte subpopulations and HPSE expression during PUUV

- 214 infection
- 215

216 Following the identification of monocytes using flow cytometry gating (Supplementary Figure 217 1), these immune cells were gated further into their well-known subpopulations of classical, intermediate, and nonclassical monocytes (CM, IM and NCM, respectively), based on their 218 219 CD14 and CD16 expression (Figure 2A). Moreover, the assessment of their frequency changes across different stages of PUUV-HFRS revealed a significant decrease in the frequency of 220 221 NCM during acute PUUV-HFRS, similarly as previously published (Vangeti et al., 2021), 222 compared to all the other groups (Figure 2A-B). Meanwhile, no visible distinctions are observed in IM and CM frequencies between the PUUV-HFRS groups, with CMs showing 223 224 consistently high frequencies in all groups.

225

Additionally, the analysis of HPSE expression in monocyte subpopulations displayed distinct patterns. Samples from acute PUUV infection exhibited significantly lower HPSE expression in NCM, compared to postacute and recovery stages of the disease. However, no significant differences are observed between PUUV-HFRS stages in IM. For CM, HPSE expression remained consistently high across all disease stages, with no significant differences observed.

231

These findings suggest a dynamic modulation of monocyte subpopulations and HPSE expression during viral infections. The pronounced decrease in NCM frequency and HPSE expression in acute PUUV-HFRS compared to postacute and recovery stages underscores the complexity of the immune response.

236

Association between monocyte responses, HPSE expression and EC shedding during acute PUUV-HFRS

240

241 To gain further understanding between the relationships of monocyte responses and EGC shedding, we investigated the associations between monocyte frequencies, their HPSE surface 242 expression, ECs (including both CECs and CEPs), soluble plasma HPSE levels and urinary 243 244 HPSE and syndecan-1 (a heparan sulfate proteoglycan and substrate for HPSE) levels during acute PUUV-HFRS. The data for the latter three parameters was published previously (Cabrera 245 246 et al., 2022). Our findings revealed a significant association between monocyte distribution and 247 plasma HPSE levels. Decreased frequencies of CMs and increased frequencies of IMs and NCMs associated with increased soluble HPSE levels by spearman correlation analysis, which 248 249 was corroborated by regression analysis for CM and IM (Fig. 3A-C). Furthermore, increased 250 frequencies of NCMs associated with increased frequencies of ECs, while the NCM surface 251 expression of HPSE associated with less ECs and increased urinary syndecan levels (Fig. 3D-252 F). While the simultaneous loss of NCMs from the circulation makes the interpretation the 253 observed significant associations rather complex, these findings suggested that NCMs (and 254 potentially IMs) shed HPSE during acute PUUV-HFRS, which resulted in increased soluble HPSE levels, increased numbers of ECs and increased amounts of EGC components in the 255 256 urine. We also analyzed the potential association between EC, monocyte subpopulations and 257 their HPSE expression with several clinical parameters (Suplementary Fig. 2A) and found that 258 NCM not only correlated with disease severity, as previously suggested (Vangeti et al., 2021), but could also explain 19.81% of the variance in disease severity ($R^2 = 0.1981$, p value = 259 260 0.0258) (Supplementary Fig. 2B). Moreover, a higher frequency of HPSE-expressing NCMs 261 in circulation was strongly linked to less hypotension (Supplementary Fig. 2C-D). On the other 262 hand, although HPSE-expressing CMs correlated with a few clinical parameters, the deeper

analyses of these associations through simple linear regressions were not as significant(Supplementary Fig. 2E-G).

- 265
- 266

267 Downregulation of monocyte surface HPSE expression is mediated by PUUV-infected
268 ECs

269

The observed modulation of HPSE expression in monocyte subsets during acute PUUV-HFRS 270 271 led us to investigate the direct effect of virus infection in monocyte HPSE expression. Since 272 PUUV is known to productively target ECs, we developed an assay in which isolated human primary monocytes were co-cultured with infected primary ECs before analyzing the surface 273 274 expression of HPSE in different monocyte subsets as well as ECs by flow cytometry. 275 Approximately 10% of ECs infected with live PUUV but none by UV-inactivated PUUV 276 expressed PUUV nucleocapsid protein which confirmed the presence of virus in the co-culture 277 (Supplementary Fig. 3), prior to the addition of monocytes at 3 days post infection. 278 Interestingly, the surface expression of HPSE significantly diminished in CMs, IMs and NCMs 279 in infected co-cultures as compared to non-infected controls inoculated with UV-inactivated virus (Fig. 4). This finding suggests that virus infection, either directly or indirectly, down-280 regulated HPSE expression in monocytes. We observed a slight but non-significant 281 282 downregulation of HPSE expression also in infected ECs.

283

284

285 Unsupervised clustering of monocyte populations in acute PUUV-HFRS

286

Finally, we wanted to gain more insight into the distinct monocyte subpopulations duringPUUV-HFRS and employed unsupervised clustering of marker expression, including HPSE,

289 CD138, HLA-DR as well as the well-described CD16 and CD14. By these means we identified 290 18 distinct monocyte populations during PUUV-HFRS (Figure 5A). Clusters 1, 2, 6, 11, 14, and 18 presented co-expression patterns indicative of IMs, since these clusters showed 291 292 increased CD16 expression while maintaining significant CD14 expression. These IM clusters displayed variable HLA-DR expressions, suggesting a dynamic transition from CMs to IMs. 293 On the other hand, clusters 3, 4, 5, 7, 8, 9, 10, 12, 13, 15 and 16 exhibited a co-expression 294 295 pattern marked by higher CD14 levels, and a lack of CD16 expression, thus indicative of CMs. Finally, cluster 17 stands out with elevated levels of CD16 together with a low CD14 marker 296 297 expression, suggesting a NCM phenotype.

298

When analyzing the trends in population changes during different disease stages, we discovered 299 300 that populations 1, 6, and 14, identified as IMs, showed increased frequencies during both acute 301 and postacute phases (Figure 5B), while other IM populations were either increased during the 302 acute phase (population 11, Figure 5C), or during the postacute phase (populations 2, 8, and 303 10, Figure 5D). Meanwhile, populations 3, 7, 13, 16, 17, and 18, identified as CMs and NCMs, 304 exhibited decreased frequencies during acute illness (Figure 5C), possibly reflecting their 305 redistribution, as previously described for NCMs (Vangeti et al., 2021), and indicating their potential involvement in response to viral infection. In contrast, populations 9, 12, and 15, 306 307 identified as CMs, decreased during the postacute phase (Figure 5D), indicating potential shifts 308 in monocyte subsets as the disease evolved.

- 309
- 310
- 311
- 312
- 313

314 **Discussion**

315

316 Investigation of the role of ECs in PUUV-HFRS is critically important, considering their central involvement in vascular responses. ECs play a pivotal role in maintaining vascular 317 318 integrity, and their dynamic alterations during viral infections can offer crucial insights into the pathophysiological processes. This study aimed to unravel the complex interplay between 319 320 PUUV infection, innate immune responses, and vascular dynamics by exploring the presence 321 of CECs as marker of EGC degradation and the potential effect monocytes may have on EGC degradation in the circulation of patients during PUUV-HFRS. Our analysis unveiled an 322 evident increase in EC counts and diminished HPSE expression in monocytes during the acute 323 324 phase of PUUV-HFRS, which gradually returned to baseline levels towards the postacute and 325 recovery stages.

326

327 By showing increased levels of CECs and CEPs in acute PUUV-HFRS, our study indicates 328 that EC integrity is compromised during acute disease, as has been speculated by many previous reports (reviewed in (Vaheri et al., 2023)). To our knowledge, this is the first report 329 330 indicating increased CECs in orthohantavirus-caused disease but is in line with previous reports showing increased levels of circulating EGC components such as syndecan-1 and increased 331 332 HPSE activity in urine of acute PUUV-HFRS (Connolly-Andersen et al., 2014; Cabrera et al., 2022). Moreover, the persistence of slightly elevated EC counts in postacute PUUV-HFRS 333 suggests ongoing vascular involvement and points towards delayed resolution of vascular 334 damage. The subsequent declining trend in EC counts during the recovery phases may signify 335 336 a resolution of acute endothelial damage, possibly through the restoration of endothelial integrity or clearance of damaged cells. 337

339 A previous study indicated a significant increase in CEPs during the late acute PUUV-HFRS, which is associated with disease severity (Krautkrämer et al., 2014). In contrast to our study, 340 in which we observed the peak of CEP response in the early acute phase (5 days post onset of 341 342 clinical symptoms), the peak in the CEP response was observed at late acute stage (11-13 days post onset of clinical symptoms). This apparent discrepancy may be due to the differences in 343 the cellular markers used to identify CEPs. Specifically, in our study we classified CEPs as 344 345 being negative for CD146 despite a previous report indicates that CD146 can be expressed in a subset of CEPs (Delorme et al., 2005). Therefore, our data may underestimate the actual CEP 346 347 counts and at least partially explain these discrepant data.

348

Monocytes and their diverse subpopulations play a pivotal role in immune surveillance and 349 350 response. To explore the origin of CECs, we inspected monocyte subpopulations and their 351 HPSE expression during PUUV infection and recovery. Employing a comprehensive gating strategy, we identified dynamic changes in CM, IM and NCM monocyte frequencies across 352 353 different stages of PUUV-HFRS, highlighting the complex nature of monocyte responses 354 during viral infections. Particularly, the observed decrease in NCM frequency during acute 355 PUUV-HFRS, which were strongly associated with disease severity, corroborates our previous findings (Vangeti et al., 2021) where we documented NCM redistribution from circulation to 356 357 affected organs, such as the kidneys, and prompting consideration of the potential local effects 358 of these cells. Interestingly, previous studies on viral diseases have revealed a similar decrease 359 of NCM frequencies during severe COVID-19 (Silvin et al., 2020).

360

Our further analysis revealed diminished frequencies of HPSE⁺ NCMs in acute PUUV-HFRS.
Furthermore, correlation and regression analyses, particularly those involving NCM
frequencies and their HPSE expression, revealed a positive association with plasma HPSE

activity and negative association with ECs, respectively, implying a potential role of these cells
in modulating endothelial responses. This was further supported by the strong power of HPSEexpressing NCMs in influencing blood pressure. These findings are in line with the idea that
once NCMs encounter PUUV-infected ECs, their surface expressed HPSE is released to
degrade the EGC. Consequently, this degradation could manifest as increased frequencies of
CECs and increased EC permeability.

370

The decreased monocyte HPSE expression by PUUV infection was further corroborated by in 371 372 vitro co-culture experiments involving PUUV-infected ECs and monocytes. These findings 373 demonstrate that the downregulation of monocyte HPSE during HFRS is likely mediated by the virus. Our data does not, however, pinpoint the exact mechanism of HPSE downregulation, 374 375 which based on the current results could be caused by monocytes directly encountering the 376 virus or by indirect mechanisms mediated by infection-activated ECs. The latter seems more 377 likely due to our previous studies, which indicate increased leukocyte (monocytes and 378 neutrophils) adhesive ability of PUUV-infected ECs as compared to non-infected ECs 379 (Strandin et al., 2018; Vangeti et al., 2021). One argument against the role of virus particles 380 per se in HPSE downregulation is also the strong downregulation of PUUV infection in the in 381 vitro infected ECs at the 3-day post infection time point, when monocytes were added to the culture. Only 10 % of ECs showed antigen positivity at this time point, which is significantly 382 383 less than the initial level of PUUV infection at 1-day time point, as shown previously (Strandin 384 et al., 2016). The decrease in PUUV infection is due to cellular antiviral responses, which could also affect monocyte HPSE expression in co-culture assay setup. 385

386

387 Unsupervised analysis based on surface marker expression elucidated distinct coexpression
388 patterns indicative of CMs, IMs, and NCMs. Monocyte populations exhibiting increased CD16

389 expression and variable HLA-DR levels were identified as IMs, and their increased frequencies 390 mostly prevailed during both acute and postacute phases, suggesting potential early-stage involvement. This is in line with our previous study, in which we observed strongly increased 391 392 HLA-DR expression in total IM cell subset in acute PUUV-HFRS (Vangeti et al., 2021). However, it is important to note that this was specific to certain IM clusters identified through 393 phenograph analysis, but not all, since frequencies of certain IM clusters were increased during 394 395 the postacute phase. It's crucial to consider these dynamics in the context of the identified monocyte subsets and their distinct roles during PUUV-HFRS progression. 396

397

398 While the overall frequencies of CMs demonstrate relative stability across different disease stages, our detailed analysis reveals population-specific dynamics within CM subsets. Notably, 399 400 populations 9, 12, and 15, identified as CMs, show decreased frequencies during the postacute 401 phase, suggesting potential shifts in these specific CM subsets as the disease progresses. This 402 nuanced observation highlights the need for a more granular understanding of the distinct 403 responses within CM populations to comprehensively unravel their roles in PUUV-HFRS 404 pathogenesis. Despite valuable insights, a limitation of this study is the lack of tissue-specific 405 analyses, which would offer a more comprehensive understanding.

406

In conclusion, our study contributes to a better understanding of PUUV-HFRS immunopathogenesis by unraveling EC and monocyte subpopulation dynamics. Observed changes underscore multi-faceted host responses during viral infections, paving the way for research on vascular complications and potential therapeutic interventions. The comprehensive investigation into EC and monocyte dynamics during PUUV-HFRS provides insights into the complex interplay between viral infections, immune responses, and vascular alterations. This investigation prompts additional exploration of the distinct roles played by monocyte subsets

in endothelial responses, offering opportunities for interventions in vascular complications
linked to PUUV-HFRS. Delving into the contributions of monocytes to endothelial glycocalyx
shredding during PUUV infection carries significant clinical implications, as it unveils
mechanisms that could be contributing to both vascular leakage and renal damage in HFRS.
Therefore, these insights may lead to the identification of novel targets for addressing these
complex clinical challenges.

421 Declaration of Competing Interest

- 422 All authors declare no financial competing interests related to the study.
- 423

424 Acknowledgements

- 425 This work was financed by grants by the Academy of Finland to T.S. (321809); grants by the
- 426 Helsinki University Hospital funds to O.V. (TYH 2021343); EU Horizon 2020 programme
- 427 VEO (874735) to O.V.; Paulon Säätiö to L.E.C.; Suomen Lääketieteen Säätiö to L.E.C.;
- 428 Finnish Kidney Foundation to L.E.C. and J.T.; Jane and Aatos Erkko foundation to O.V.; and
- 429 Finnish Cultural Foundation Pirkanmaa Regional fund to J.T. The funders had no role in study
- 430 design, data collection and analysis, nor decision to publish, or preparation of the manuscript.
- 431 The authors also thank S. Mäki and M. Utriainen for expert technical assistance.

432 References

| 433 | |
|-----|---|
| 434 | Becker, B. F., Jacob, M., Leipert, S., Salmon, A. H. J., and Chappell, D. (2015). Degradation of the |
| 435 | endothelial glycocalyx in clinical settings: Searching for the sheddases. Br J Clin Pharmacol 80, |
| 436 | 389–402. doi: 10.1111/bcp.12629 |
| 437 | |
| 438 | Cabrera, L. E., Schmotz, C., Saleem, M. A., Lehtonen, S., Vapalahti, O., Vaheri, A., et al. (2022). |
| 439 | Increased Heparanase levels in urine during acute Puumala Orthohantavirus infection are associated |
| 440 | with disease severity. Viruses 14. doi: 10.3390/v14030450 |
| 441 | |
| 442 | Connolly-Andersen, A. M., Thunberg, T., and Ahlm, C. (2014). Endothelial activation and repair during |
| 443 | hantavirus infection: Association with disease outcome. Open Forum Infect Dis 1. doi: |
| 444 | 10.1093/ofid/ofu027 |
| 445 | |
| 446 | Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S. Y., Senechal, B., et al. (2010). Human CD14dim |
| 447 | Monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33, |
| 448 | 375–386. doi: 10.1016/j.immuni.2010.08.012 |
| 449 | |
| 450 | Delorme, B., Basire, A., Gentile, C., Sabatier, F., Monsonis, F., Desouches, C., et al. (2005). Presence of |
| 451 | endothelial progenitor cells, distinct from mature endothelial cells, within CD146+ blood cells. |
| 452 | Thromb Haemost 94, 1270-1279. doi: 10.1160/TH05-07-0499 |
| 453 | |
| 454 | Drost, C. C., Rovas, A., Osiaevi, I., Rauen, M., van der Vlag, J., Buijsers, B., et al. (2022). Heparanase Is |
| 455 | a putative mediator of endothelial glycocalyx damage in COVID-19 – A proof-of-concept study. |

- 456 Front Immunol 13. doi: 10.3389/fimmu.2022.916512 457
- Du, H., Hu, H., Li, J., Wang, X., Jiang, H., Lian, J., et al. (2023). High levels of exfoliated fragments 458 459 following glycocalyx destruction in hemorrhagic fever with the renal syndrome are associated with 460 mortality risk. Front Med (Lausanne) 10. doi: 10.3389/fmed.2023.1096353

| 462 | Fosse, J. H., Haraldsen, G., Falk, K., and Edelmann, R. (2021). Endothelial cells in emerging viral |
|-----|--|
| 463 | infections. Front Cardiovasc Med 8. doi: 10.3389/fcvm.2021.619690 |
| 464 | |
| 465 | Gren, S. T., Rasmussen, T. B., Janciauskiene, S., Hakansson, K., Gerwien, J. G., and Grip, O. (2015). A |
| 466 | single-cell gene-expression profile reveals inter-cellular heterogeneity within human monocyte |
| 467 | subsets. PLoS One 10. doi: 10.1371/journal.pone.0144351 |
| 468 | |
| 469 | Guervilly, C., Burtey, S., Sabatier, F., Cauchois, R., Lano, G., Abdili, E., et al. (2020). Circulating |
| 470 | Endothelial Cells as a marker of endothelial injury in severe COVID-19. Journal of Infectious |
| 471 | Diseases 222, 1789–1793. doi: 10.1093/infdis/jiaa528 |
| 472 | |
| 473 | Hepojoki, J., Vaheri, A., and Strandin, T. (2014). The fundamental role of endothelial cells in hantavirus |
| 474 | pathogenesis. Front Microbiol 5. doi: 10.3389/fmicb.2014.00727 |
| 475 | |
| 476 | Kinaneh, S., Khamaysi, I., Karram, T., and Hamoud, S. (2021). Heparanase as a potential player in SARS- |
| 477 | CoV-2 infection and induced coagulopathy. Biosci Rep 41. doi: 10.1042/BSR20210290 |
| 478 | |
| 479 | Krautkrämer, E., Grouls, S., Hettwer, D., Rafat, N., Tönshoff, B., and Zeier, M. (2014). Mobilization of |
| 480 | circulating endothelial progenitor cells correlates with the clinical course of Hantavirus disease. J |
| 481 | Virol 88, 483–489. doi: 10.1128/jvi.02063-13 |
| 482 | |
| 483 | Masola, V., Greco, N., Gambaro, G., Franchi, M., and Onisto, M. (2022). Heparanase as active player in |
| 484 | endothelial glycocalyx remodeling. Matrix Biol Plus 13. doi: 10.1016/j.mbplus.2021.100097 |
| 485 | |
| 486 | Reitsma, S., Slaaf, D. W., Vink, H., Van Zandvoort, M. A. M. J., and Oude Egbrink, M. G. A. (2007). |
| 487 | The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch 454, 345- |
| 488 | 359. doi: 10.1007/s00424-007-0212-8 |
| 489 | |

| 490 | Sasaki, N., Higashi, N., Taka, T., Nakajima, M., and Irimura, T. (2004). Cell surface localization of |
|-----|--|
| 491 | Heparanase on Macrophages regulates degradation of extracellular matrix Heparan Sulfate. The |
| 492 | Journal of Immunology 172, 3830-3835. doi: 10.4049/jimmunol.172.6.3830 |
| 493 | |
| 494 | Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A. G., Dubuisson, A., Derosa, L., et al. (2020). Elevated |
| 495 | calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182, |
| 496 | 1401-1418.e18. doi: 10.1016/j.cell.2020.08.002 |
| 497 | |
| 498 | Sironen, T., Sane, J., Lokki, M. L., Meri, S., Andersson, L. C., Hautala, T., et al. (2017). Fatal Puumala |
| 499 | hantavirus disease: Involvement of complement activation and vascular leakage in the pathobiology. |
| 500 | Open Forum Infect Dis 4. doi: 10.1093/ofid/ofx229 |
| 501 | |
| 502 | Strandin, T., Hepojoki, J., Laine, O., Mäkelä, S., Klingström, J., Lundkvist, A., et al. (2016). Interferons |
| 503 | induce STAT1-dependent expression of Tissue Plasminogen Activator, a pathogenicity factor in |
| 504 | Puumala Hantavirus disease. Journal of Infectious Diseases 213, 1632-1641. doi: |
| 505 | 10.1093/infdis/jiv764 |
| 506 | |
| 507 | Strandin, T., Mäkelä, S., Mustonen, J., and Vaheri, A. (2018). Neutrophil activation in acute hemorrhagic |
| 508 | fever with renal syndrome is mediated by hantavirus-infected microvascular endothelial cells. Front |
| 509 | Immunol 9. doi: 10.3389/fimmu.2018.02098 |
| 510 | |
| 511 | Temonen, M., Vapalahti, O., Holthöfer, H., Brummer-Korvenkontio, M., Vaherp, A., and Lankinen, H. |
| 512 | (1993). Susceptibility of human cells to Puumala virus infection. Journal of General Virology 74, |
| 513 | 515–518. |
| 514 | |
| 515 | Tietäväinen, J., Mäkelä, S., Huhtala, H., Pörsti, I. H., Strandin, T., Vaheri, A., et al. (2021). The clinical |
| 516 | presentation of Puumala Hantavirus induced Hemorrhagic Fever with Renal Syndrome Is related to |
| 517 | plasma glucose concentration. Viruses 13, 1177. doi: 10.3390/v13061177 |
| 518 | |

| 519 | Vaheri, A., Smura, T., Vauhkonen, H., Hepojoki, J., Sironen, T., Strandin, T., et al. (2023). Puumala |
|-----|---|
| 520 | Hantavirus infections show extensive variation in clinical outcome. Viruses 15. doi: |
| 521 | 10.3390/v15030805 |
| 522 | |
| 523 | Vangeti, S., Strandin, T., Liu, S., Tauriainen, J., Raïsänen-Sokolowski, A., Cabrera, L. E., et al. (2021). |
| 524 | Monocyte subset redistribution from blood to kidneys in patients with Puumala virus caused |
| 525 | hemorrhagic fever with renal syndrome. PLoS Pathog 17. doi: 10.1371/journal.ppat.1009400 |
| 526 | |
| 527 | Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et al. (2020). |
| 528 | Endothelial cell infection and endothelitis in COVID-19. The Lancet 395, 1417-1418. doi: |
| 529 | 10.1016/S0140-6736(20)30937-5 |
| 530 | |
| 531 | Williams, H., Mack, C., Baraz, R., Marimuthu, R., Naralashetty, S., Li, S., et al. (2023). Monocyte |
| 532 | differentiation and heterogeneity: inter-subset and interindividual differences. Int J Mol Sci 24. doi: |
| 533 | 10.3390/ijms24108757 |
| 534 | |
| 535 | Zawada, A. M., Rogacev, K. S., Rotter, B., Winter, P., Marell, R. R., Fliser, D., et al. (2011). SuperSAGE |
| 536 | evidence for CD14++CD16+ monocytes as a third monocyte subset. <i>Blood</i> 118. doi: 10.1182/blood- |
| 537 | 2011-01-326827 |
| 538 | |
| 539 | |

Figures & figure legends 540



Ε





D



CEP 40 n=15 30 20 Count n=14 n=4 n=7 n=10 10 n=23 n=20 n=23 0 4 5 6 7 9 8 20-30 180 365 Days AOF

| 542 | Figure 1. Identification and quantification of endothelial cells in acute PUUV-HFRS Patients. (A) Flow |
|-----|--|
| 543 | cytometry gating strategy for the identification of endothelial cells (ECs) from peripheral blood mononuclear cells |
| 544 | (PBMCs). The gating strategy involves a stepwise selection process, starting with morphological gating for debris |
| 545 | exclusion (FSC vs. SSC plot), followed by singlet gating to exclude doublets (FSC-A vs FSC-H), and a dump |
| 546 | channel for the exclusion of dead cells and CD3, CD56, CD19 expressing cell populations. Subsequently, a |
| 547 | double-negative gate for HLA-DR and CD16 is applied, followed by a CD14 ⁻ /CD45 ^{-/dim} , to ensure the exclusion |
| 548 | of background when identifying rare cells such as ECs. Then, the final gate plots CD133 and CD146 markers, to |
| 549 | identify the circulating EC populations of interest: CD133 ⁻ /CD146 ⁺ for mature CECs and CD133 ⁺ /CD146 ⁻ for |
| 550 | CEPs. |
| 551 | (B-C) Graph depicting individual counts of (B) Mature CD146 ⁺ /CD133 ⁻ CECs and (C) CD146 ⁻ /CD133 ⁺ CEPs |
| 552 | obtained from flow cytometry analysis. The x-axis illustrates different groups: acute, postacute, and recovered (6 |
| 553 | months and 12 months post-infection) PUUV-HFRS patients. Each data point represents a CEC count from one |
| 554 | individual within the specified group. |
| 555 | (D-E) Timeline graphs of the (D) CEC and (E) CEP cell count means (± SD) from PUUV-infected patients during |
| 556 | acute, postacute, and recovery phases. |
| 557 | p < 0.05; p values calculated with Kruskall-Wallis test. |
| 558 | EC = endothelial cell; CEC = circulating endothelial cells; CEP = circulating endothelial progenitors; AOF = |
| 559 | after onset of fever; FSC = forward scatter; SSC = side scatter; PUUV = Puumala orthohantavirus; PUUV- |
| 560 | HFRS = Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; SD = standard deviation. |

561







572 *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P values calculated with 2-way ANOVA Tukey's multiple 573 comparisons test.

574 *PUUV-HFRS* = *Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; HPSE* = *heparanase;*

575 *CM* = *classical monocyte; IM* = *intermediate monocyte; NCM* = *nonclassical monocyte.*



577 Figure 3. Multiparameter correlation analysis in PUUV-HFRS. (A) Correlation matrix depicting the 578 relationships between flow cytometry parameters, including EC counts (including both CECs and CEPs), 579 monocyte subpopulation frequencies, and HPSE expression in monocytes, alongside measured syndecan-1 in 580 urine and HPSE levels in plasma and urine and days AOF.

- 581 (B) Regression analysis demonstrating a negative association between the frequency of CM and plasma HPSE
- 582 levels.
- 583 (C) Regression analysis revealing a positive link between the frequency of IM and plasma HPSE levels.
- (D) Positive regression analysis displaying the correlation between the frequency of NCM and EC counts from
- flow cytometry.
- 586 (E) Regression analysis illustrating the negative correlation between the frequency of HPSE⁺ NCM and EC counts
- from flow cytometry.
- 588 (F) Positive regression analysis between HPSE⁺ NCM and urinary syndecan:creatinine ratio.
- 589 P values were determined using Pearson correlation and are denoted as follows: *p < 0.05, **p < 0.01, ***p < 522
- **590** 0.001.
- 591 *PUUV-HFRS* = *Puumala orthohantavirus-caused hemorrhagic fever with renal syndrome; HPSE* = *heparanase;*
- 592 CM = Classical monocytes; NCM = Nonclassical monocytes; EC = endothelial cells; HPSE⁺ NCM =
- 593 *heparanase-expressing nonclassical monocytes; U-syndecan/creatinine = urinary syndecan:creatinine ratio;*
- **594** AOF = after onset of fever.





596



598 Figure 4. Heparanase expression is decreased in monocyte subpopulations by PUUV-infected endothelial 599 cells. BECs were infected live or UV-inactivated PUUV for 3 days after which monocytes isolated from healthy 600 controls were introduced in the co-culture for 24-hr. Cells were stained with an antibody panel allowing the 601 identification of surface HPSE expression in CMs, IMs, NCMs and ECs by flow cytometry. The statistical 602 differences between UV- and live PUUV-infected co-cultures were assessed by Kruskal-Wallis test. *p < 0.05, 603 **p < 0.01, ***p < 0.001.

⁶⁰⁴ PUUV = Puumala orthohantavirus; HPSE + = heparanase-expressing cell; BECs = blood microvascular605 endothelial cells.





608 Figure 5. Unsupervised identification of monocyte subpopulations in PUUV-HFRS disease stages. (A) A 609 heatmap presenting the MFI of surface markers (HPSE, CD138, HLA-DR, CD16, and CD14) across 18 monocyte 610 subpopulations identified through phenograph clustering analysis. Each row corresponds to a subpopulation, with 611 color intensity indicating the MFI levels of the respective surface markers.

- 612 (B–D) Graphical representation showing the percentage of monocyte subpopulations during different disease
- 613 phases (acute, postacute, 6 months, and 12 months). Dots connected by line graphs indicate trends in
- 614 subpopulation changes.
- 615 (B) Changes in acute and postacute phases are seen in populations 1, 6, and 14 frequencies, which are increased
- 616 during these phases, compared to recovery.
- 617 (C) Changes during the acute phase of the disease are detected in populations 3, 7, 11, 13, 16, 17 and 18, where
- 618 the majority exhibit a decrease in frequency during this phase, while the frequency of population 11 shows an
- 619 increase.
- 620 (D) Graph displaying the percentage variations of monocyte subpopulations (pops 2, 8, 9, 10, 12, and 15) specific
- 621 to the postacute phase in comparison to other phases.
- 622 MFI= mean fluorescence intensity; HPSE = heparanase; pop = population; PUUV-HFRS = Puumala
- 623 *orthohantavirus-caused hemorrhagic fever with renal syndrome.*

Supplementary figure legends 625

- 626 Supplementary Figure 1. Flow cytometry gating strategy for monocyte identification. Flow cytometry gating 627 strategy outlining the stepwise selection process for identifying monocytes from PBMCs. The strategy consists of 628 six sequential gates to ensure accurate and specific identification: (a) Morphological gating (FSC vs. SSC plot) to 629 exclude debris. (b) Singlet gating to exclude doublets, by plotting FSC area vs. height. (c) Dump channel gate to 630 exclude dead cells and CD3, CD56, and CD19 expressing cell populations. (d) CD45 gating, where the CD45⁺ 631 cell population is selected, represented by CD45 vs. side scatter (SSC) plot. (e) HLA-DR gating, isolating HLA-632 DR⁺ cells with high side scatter (SSC) to capture monocytes within PBMCs. (f) CD14 vs. CD16 gating, excluding 633 double-negative cells in the CD14 vs. CD16 plot to specifically identify monocytes. FSC = forward scatter; SSC 634 = side scatter; PBMC = peripheral blood mononuclear cell; FSC-A = forward scatter area; FSC-H = forward
- 635 scatter height.

| 637 | Supplementary Figure 2. Correlation and regression analyses of ECs, monocyte subpopulations, HPSE |
|-----|---|
| 638 | expression, and clinical parameters in PUUV-HFRS. (A) Extended correlation matrix depicting the Spearman's |
| 639 | rank correlation coefficients between flow cytometry-derived monocyte subpopulation counts, their respective |
| 640 | HPSE expressions, plasma P-HPSE, urine U-HPSE:creat, U-syndecan-1:creat, and various clinical parameters. |
| 641 | Clinical parameters are located together and delimited by a black box, where significant correlations ($p<0.05$) are |
| 642 | marked with a surrounding dashed line. (B-G) Simple linear regression analyses illustrating the relationships |
| 643 | between: (B) NCM frequency and disease severity score, (C) HPSE ⁺ NCM frequency and minimum diastolic |
| 644 | blood pressure, (D) HPSE ⁺ NCM frequency and minimum systolic blood pressure, (E) HPSE ⁺ CM frequency and |
| 645 | maximum diuresis per day, (F) HPSE ⁺ CM frequency and maximum systolic blood pressure, and (G) HPSE ⁺ CM |
| 646 | frequency and duration of fever. $EC = endothelial cells; CM = classical monocytes; IM = intermediate$ |
| 647 | $monocytes; NCM = non-classical monocytes; HPSE = heparanase; HPSE^+ = HPSE-expressing cells; P-HPSE$ |
| 648 | = plasma heparanase; U-HPSE/creat = urine heparanase:creatinine ratio; U-syndecan-1/creat = urine |
| 649 | syndecan-1:creatinine ratio; LOS = length of stay; min = minimum; max = maximum; SBP = systolic blood |
| 650 | pressure; DBP = diastolic blood pressure; creat = creatinine; WBC = white blood cells; thromb = thrombocytes; |
| 651 | CRP = C-reactive protein; U-alb:creat = urine albumin:creatinine ratio; days $AOF = days$ after onset of fever. |

- 653 Supplementary Figure 3. Immunofluorescence of UV-inactivated PUUV and live PUUV-infected blood
- 654 microvascular endothelial cells (BECs) prior to coculture with monocytes. BECs were infected with live or
- 655 UV-inactivated PUUV for 3 days and stained for PUUV nucleocapsid protein N and nucleus by PUUV N-specific
- 656 rabbit sera (green) and Hoechst33342 (blue), respectively. Overlay images of green and blue fluorescence are
- 657 shown. UV = ultraviolet; PUUV = Puumala orthohantavirus; N = nucleocapsid; BEC = blood microvascular
- 658 endothelial cells.
- 659



В







С









С



Α













Β



С







Ε





medRxiv preprint doi: https://doi.org/10.1101/2024#08.25.24312546; this version posted August 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

| | | | | | Σ | lt i | s g na | a | agai | ilabl | e g n | der | a | ୍ଷ୍ପ | /-NC | 24.0 |) Inte | erna | tign | al <mark>s</mark> ic | e <mark>s</mark> s | e. | | | | ą | | at | |
|--------------------|-------|-------|-------|-------|--------|-------|-------------------|-------|-------|-------|--------------|-------|-------|-------|------------|--------|-------------|-------|-------|----------------------|--------------------|------------|------------|------------|-------|-------|------------|-------|-------|
| | ount | | | | с Ш | ≦ | z # | SE (| SE/c | ndec | rity_ | | r (du | oital | SBP | SBP | DBP | OBP | ht lo | diure | liure | crea | WBC | Hct | çt | hron | CRP | cre: | ION |
| | ပ္ထိ | Ň | Σ | NCM | IPSI | IPSI | IS | ЧH- | Η̈́ | J-sy | seve | Age | eve | losp | Jax | Ain \$ | / ax | lin [| Veig | Jax | Ain o | Jax | Jax | Jax | Ain F | /in t | Aax | J-alb | Jays |
| EC count | 1.00 | 0.01 | -0.13 | 0.42 | -0.24 | 0.02 | -0.44 | -0.08 | 0.07 | -0.55 | 0.11 | 0.34 | -0.14 | 0.14 | 0.02 | - | -0.04 | -0.12 | 0.35 | -0.15 | -0.23 | 0.11 | 0.10 | 0.43 | 0.13 | 0.03 | 0.24 | -0.28 | -0.21 |
| СМ | 0.01 | 1.00 | -0.97 | -0.14 | 0.20 | -0.38 | -0.33 | -0.59 | -0.23 | -0.04 | 0.26 | 0.13 | 0.31 | 0.07 | -0.06 | 0.07 | 0.20 | -0.20 | 0.08 | -0.06 | -0.32 | 0.31 | -0.06 | -0.38 | -0.19 | 0.18 | 0.15 | -0.05 | 0.42 |
| IM | -0.13 | -0.97 | 1.00 | -0.05 | -0.25 | 0.31 | 0.35 | 0.55 | 0.20 | 0.02 | -0.22 | -0.15 | -0.31 | -0.05 | 0.02 | -0.16 | -0.23 | 0.15 | -0.13 | 0.12 | 0.33 | -0.29 | 0.05 | 0.35 | 0.17 | -0.18 | -0.20 | 0.03 | -0.39 |
| NCM | 0.42 | -0.14 | -0.05 | 1.00 | 0.08 | 0.13 | -0.08 | 0.41 | 0.04 | -0.70 | -0.51 | 0.09 | -0.15 | -0.17 | -0.03 | 0.11 | 0.21 | 0.07 | -0.23 | -0.38 | -0.01 | -0.42 | -0.35 | -0.01 | 0.30 | 0.19 | 0.32 | 0.19 | -0.17 |
| HPSE+ CM | -0.24 | 0.20 | -0.25 | 0.08 | 1.00 | 0.43 | -0.06 | -0.40 | 0.47 | 0.36 | -0.09 | -0.25 | 0.43 | -0.32 | -0.43 | 0.13 | -0.13 | -0.02 | -0.35 | -0.43 | | -0.15 | -0.11 | -0.02 | 0.18 | -0.13 | 0.16 | 0.03 | -0.02 |
| HPSE+ IM | 0.02 | -0.38 | 0.31 | 0.13 | 0.43 | 1.00 | -0.09 | 0.18 | 0.23 | 0.02 | -0.15 | 0.13 | 0.10 | -0.28 | -0.21 | -0.08 | -0.18 | -0.17 | -0.13 | -0.36 | -0.17 | -0.22 | 0.10 | 0.25 | 0.38 | 0.02 | -0.08 | | -0.29 |
| HPSE+ NCM | -0.44 | -0.33 | 0.35 | -0.08 | -0.06 | -0.09 | 1.00 | 0.19 | -0.39 | 0.80 | -0.32 | -0.36 | -0.19 | -0.27 | 0.13 | 0.43 | -0.03 | 0.45 | -0.17 | 0.06 | 0.21 | -0.14 | -0.27 | -0.21 | -0.01 | 0.37 | -0.34 | 0.10 | -0.12 |
| P-HPSE (ng/mL) | -0.08 | -0.59 | 0.55 | 0.41 | -0.40 | 0.18 | 0.19 | 1.00 | -0.20 | -0.51 | -0.27 | -0.08 | -0.17 | 0.12 | 0.22 | -0.09 | 0.21 | -0.03 | -0.06 | 0.09 | 0.19 | -0.23 | -0.16 | -0.12 | -0.04 | 0.03 | -0.09 | 0.30 | 0.03 |
| U-HPSE/creat | 0.07 | -0.23 | 0.20 | 0.04 | 0.47 | 0.23 | -0.39 | -0.20 | 1.00 | -0.19 | -0.14 | 0.14 | 0.41 | -0.14 | -0.10 | -0.36 | 0.09 | -0.31 | -0.13 | -0.46 | -0.43 | -0.52 | 0.22 | 0.44 | 0.18 | -0.54 | -0.14 | 0.33 | -0.47 |
| U-syndecan-1/creat | -0.55 | -0.04 | 0.02 | -0.70 | 0.36 | 0.02 | 0.80 | -0.51 | -0.19 | 1.00 | 0.50 | -0.60 | 0.13 | -0.36 | -0.42 | 0.22 | -0.30 | 0.15 | -0.23 | 0.39 | 0.19 | 0.18 | 0.36 | 0.03 | 0.03 | -0.24 | -0.07 | 0.33 | 0.11 |
| Severity_score | 0.11 | 0.26 | -0.22 | -0.51 | -0.09 | -0.15 | -0.32 | -0.27 | -0.14 | 0.50 | 1.00 | 0.26 | -0.06 | 0.51 | 0.11 | -0.19 | -0.04 | -0.26 | 0.62 | 0.54 | -0.17 | 0.87 | 0.64 | 0.35 | -0.52 | -0.40 | 0.01 | -0.09 | 0.35 |
| Age | 0.34 | 0.13 | -0.15 | 0.09 | -0.25 | 0.13 | -0.36 | -0.08 | 0.14 | -0.60 | 0.26 | 1.00 | -0.27 | 0.29 | 0.33 | -0.06 | 0.12 | -0.10 | 0.51 | 0.11 | -0.37 | 0.35 | 0.23 | 0.24 | -0.22 | 0.18 | -0.07 | -0.07 | |
| Fever (duration) | -0.14 | 0.31 | -0.31 | -0.15 | 0.43 | 0.10 | -0.19 | -0.17 | 0.41 | 0.13 | -0.06 | -0.27 | 1.00 | 0.11 | -0.03 | 0.12 | 0.33 | -0.21 | -0.19 | -0.22 | -0.02 | -0.20 | -0.26 | -0.33 | -0.02 | -0.21 | 0.26 | 0.13 | 0.25 |
| Hospital LOS | 0.14 | 0.07 | -0.05 | -0.17 | -0.32 | -0.28 | -0.27 | 0.12 | -0.14 | -0.36 | 0.51 | 0.29 | 0.11 | 1.00 | 0.20 | -0.41 | 0.14 | -0.19 | 0.32 | 0.33 | -0.28 | 0.38 | 0.05 | 0.01 | -0.70 | -0.34 | 0.16 | 0.15 | 0.50 |
| Max SBP | 0.02 | -0.06 | 0.02 | -0.03 | -0.43 | -0.21 | 0.13 | 0.22 | -0.10 | -0.42 | 0.11 | 0.33 | -0.03 | 0.20 | 1.00 | 0.25 | 0.57 | 0.39 | 0.67 | 0.41 | | 0.30 | 0.04 | | -0.44 | | -0.25 | 0.01 | 0.11 |
| Min SBP | | 0.07 | -0.16 | 0.11 | 0.13 | -0.08 | 0.43 | -0.09 | -0.36 | 0.22 | -0.19 | -0.06 | 0.12 | -0.41 | 0.25 | 1.00 | 0.10 | 0.46 | 0.23 | 0.20 | 0.29 | 0.11 | -0.17 | -0.32 | 0.09 | 0.46 | -0.12 | -0.32 | 0.12 |
| Max DBP | -0.04 | 0.20 | -0.23 | 0.21 | -0.13 | -0.18 | -0.03 | 0.21 | 0.09 | -0.30 | -0.04 | 0.12 | 0.33 | 0.14 | 0.57 | 0.10 | 1.00 | 0.24 | 0.09 | 0.01 | -0.31 | -0.03 | -0.14 | -0.06 | -0.17 | -0.20 | 0.30 | 0.44 | 0.14 |
| Min DBP | -0.12 | -0.20 | 0.15 | 0.07 | -0.02 | -0.17 | 0.45 | -0.03 | -0.31 | 0.15 | -0.26 | -0.10 | -0.21 | -0.19 | 0.39 | 0.46 | 0.24 | 1.00 | 0.09 | 0.09 | 0.22 | -0.12 | -0.04 | 0.10 | -0.01 | -0.09 | -0.14 | -0.09 | -0.09 |
| Weight loss | 0.35 | 0.08 | -0.13 | -0.23 | -0.35 | -0.13 | -0.17 | -0.06 | -0.13 | -0.23 | 0.62 | 0.51 | -0.19 | 0.32 | 0.67 | 0.23 | 0.09 | 0.09 | 1.00 | 0.46 | 0.01 | 0.73 | 0.45 | 0.17 | -0.56 | -0.02 | -0.15 | -0.30 | 0.11 |
| Max diuresis | -0.15 | -0.06 | 0.12 | -0.38 | -0.43 | -0.36 | 0.06 | 0.09 | -0.46 | 0.39 | 0.54 | 0.11 | -0.22 | 0.33 | 0.41 | 0.20 | 0.01 | 0.09 | 0.46 | 1.00 | 0.35 | 0.68 | 0.15 | 0.02 | -0.46 | -0.07 | -0.31 | -0.09 | 0.56 |
| Min diuresis | -0.23 | -0.32 | 0.33 | -0.01 | | -0.17 | 0.21 | 0.19 | -0.43 | 0.19 | -0.17 | -0.37 | -0.02 | -0.28 | | 0.29 | -0.31 | 0.22 | 0.01 | 0.35 | 1.00 | -0.11 | -0.15 | -0.18 | 0.19 | 0.01 | -0.11 | -0.25 | 0.08 |
| Max creat | 0.11 | 0.31 | -0.29 | -0.42 | -0.15 | -0.22 | -0.14 | -0.23 | -0.52 | 0.18 | 0.87 | 0.35 | -0.20 | 0.38 | 0.30 | 0.11 | -0.03 | -0.12 | 0.73 | 0.68 | -0.11 | 1.00 | 0.40 | 0.15 | -0.56 | | -0.20 | -0.22 | 0.48 |
| Max WBC | 0.10 | -0.06 | 0.05 | -0.35 | -0.11 | 0.10 | -0.27 | -0.16 | 0.22 | 0.36 | 0.64 | 0.23 | -0.26 | 0.05 | 0.04 | -0.17 | -0.14 | -0.04 | 0.45 | 0.15 | -0.15 | 0.40 | 1.00 | 0.63 | -0.03 | -0.44 | -0.13 | 0.07 | -0.33 |
| Max Hct | 0.43 | -0.38 | 0.35 | -0.01 | -0.02 | 0.25 | -0.21 | -0.12 | 0.44 | 0.03 | 0.35 | 0.24 | -0.33 | 0.01 | | -0.32 | -0.06 | 0.10 | 0.17 | 0.02 | -0.18 | 0.15 | 0.63 | 1.00 | 0.20 | -0.55 | -0.10 | 0.04 | -0.49 |
| Min Hct | 0.13 | -0.19 | 0.17 | 0.30 | 0.18 | 0.38 | -0.01 | -0.04 | 0.18 | 0.03 | -0.52 | -0.22 | -0.02 | -0.70 | -0.44 | 0.09 | -0.17 | -0.01 | -0.56 | -0.46 | 0.19 | -0.56 | -0.03 | 0.20 | 1.00 | 0.21 | -0.04 | -0.08 | -0.50 |
| Min thromb | 0.03 | 0.18 | -0.18 | 0.19 | -0.13 | 0.02 | 0.37 | 0.03 | -0.54 | -0.24 | -0.40 | 0.18 | -0.21 | -0.34 | | 0.46 | -0.20 | -0.09 | -0.02 | -0.07 | 0.01 | | -0.44 | -0.55 | 0.21 | 1.00 | -0.27 | -0.23 | 0.04 |
| Max CRP | 0.24 | 0.15 | -0.20 | 0.32 | 0.16 | -0.08 | -0.34 | -0.09 | -0.14 | -0.07 | 0.01 | -0.07 | 0.26 | 0.16 | -0.25 | -0.12 | 0.30 | -0.14 | -0.15 | -0.31 | -0.11 | -0.20 | -0.13 | -0.10 | -0.04 | -0.27 | 1.00 | 0.15 | 0.01 |
| U-alb:creat | -0.28 | -0.05 | 0.03 | 0.19 | 0.03 | | 0.10 | 0.30 | 0.33 | 0.33 | -0.09 | -0.07 | 0.13 | 0.15 | 0.01 | -0.32 | 0.44 | -0.09 | -0.30 | -0.09 | -0.25 | -0.22 | 0.07 | 0.04 | -0.08 | -0.23 | 0.15 | 1.00 | -0.14 |
| Days AOF | -0.21 | 0.42 | -0.39 | -0.17 | -0.02 | -0.29 | -0.12 | 0.03 | -0.47 | 0.11 | 0.35 | | 0.25 | 0.50 | 0.11 | 0.12 | 0.14 | -0.09 | 0.11 | 0.56 | 0.08 | 0.48 | -0.33 | -0.49 | -0.50 | 0.04 | 0.01 | -0.14 | 1.00 |







R²= 0.1981







D

1.0



UV-inactivated PUUV

Live PUUV



